Daiichi Sankyo Company, Limited

LILLY (ELI) & COMPANY - Effient Recommendations in PCI-STEMI Guidelines [Press Release]
PRNewswire | 4 days 17 hours 40 minutes ago
Date: November 18, 2009 Refer to: Tammy Hull Eli Lilly and Company 317-651-9116 (office) 317-614-5132 (cell) Kimberly Wix Daiichi Sankyo (U.S.A.) 973-944-2338 (office) 908-656-5447 (cell) Shigemichi Kondo Daiichi Sankyo (Tokyo) 81-3-6225-1126 (office)

MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections [Press Release]
MarketWire | 34 days 7 hours 42 minutes ago
MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwire) -- 10/20/09 --

LILLY (ELI) & COMPANY - Research Update [Press Release]
PRNewswire | 6 days 22 hours 47 minutes ago
Date: Nov. 15, 2009 Refer to: Derin Denham Eli Lilly and Company +1-317-277-6749 (office) +1-317-370-1435 (cell) Dr. Michaela Paudler-Debus Daiichi Sankyo Europe GmbH +49-(0)89-78 08 685 (office) +49-(0)172-845 8974 (cell) Shigemichi Kondo Daiichi Sankyo (Tokyo) 81-3-6225-1126 (office)

New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI [Press Release]
PRNewswire | 4 days 18 hours 2 minutes ago
...medical director for Daiichi Sankyo, Inc. "Based on the...forming around stents." Daiichi Sankyo Company, Limited , and Eli Lilly and Company co-developed Effient...antiplatelet agent discovered by Daiichi Sankyo and its Japanese research...

Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease [Press Release]
PRNewswire | 7 days 16 hours 13 minutes ago
...ACS.(3) Daiichi Sankyo Company, Limited , and Eli Lilly and Company co-developed...discovered by Daiichi Sankyo and its Japanese...Eli Lilly and Company, +1-317...Kimberly Wix, Daiichi Sankyo (U.S.A...

Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical Market Analysis [Press Release]
Business Wire | 5 days 3 hours 12 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/ff5934/antibiotics_glob) has announced the addition of the "Antibiotics - Global Trends" report to their offering.

Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) [Press Release]
PRNewswire | 82 days 7 hours 11 minutes ago
...Ranbaxy Laboratories Limited (RLL), India...largest pharmaceutical company. RPI is engaged...Ranbaxy Laboratories Limited, headquartered...international pharmaceutical company producing a wide...a subsidiary of Daiichi Sankyo Company, Ltd...

Effient(TM) is Now Available in Pharmacies [Press Release]
PRNewswire | 110 days 5 hours 11 minutes ago
...Exchange. Daiichi Sankyo and Lilly undertake...DSLLOGO Eli Lilly and Company CONTACT: Tammy Hull, Eli Lilly and Company, +1-317-651...Kimberly Wix, Daiichi Sankyo Inc. (U.S.A...Kondo, DaiichiSankyo Limited (Tokyo), 81...

Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets [Press Release]
PRNewswire | 91 days 3 hours 12 minutes ago
...Ranbaxy Laboratories Limited (RLL), India...largest pharmaceutical company. RPI is engaged...Ranbaxy Laboratories Limited, headquartered...international pharmaceutical company producing a wide...a subsidiary of Daiichi Sankyo Company, Ltd...

Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets [Press Release]
PRNewswire | 104 days 4 hours 42 minutes ago
...Ranbaxy Laboratories Limited (RLL), India...largest pharmaceutical company. RPI is engaged...Ranbaxy Laboratories Limited, headquartered...international pharmaceutical company producing a wide...a subsidiary of Daiichi Sankyo Company, Ltd...

Welchol(R) (colesevelam HCl) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia [Press Release]
PRNewswire | 47 days 6 hours 9 minutes ago
PARSIPPANY, N.J., Oct. 7 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol(R) (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin afte...

Reportlinker Adds Prescription Drugs Report [Press Release]
PRNewswire | 76 days 3 hours 41 minutes ago
...Ranbaxy Laboratories Limited, Sanofi-Aventis SA...Takeda Pharmaceutical Company Limited, Teva Pharmaceutical...secondary research. Company profiles are mostly...II-93 Forest and Daiichi Sankyo Sign Contract to Co...